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Clinical data exercise angina in 30% of the patients, acute coronary syn-
droms in 61%, silent ischaemia in 7% and heart failure in 2%.
Procedural data all stents have been implanted under angiographic con-
trol, only 2 beeing imaged by IVUS, in de novo lesions, through a radial
approach with 6 French guiding catheters, following mandatory predilatation.
67% of patents had single vessel desease, 33% multivessel desease. Left ante-
rior descending artery was the target vessel in 64%, the left circumflex in 19%
and the right coronary artery in 26%. 212 stents have neen sdelivered with
only one failure. 25 patients underwent metallic stenting of other arteries. Side
branch angioplasty had to be performed in 4 cases. 
In hospital follow up No death. One complication withe non Q wave myo-
cardial infraction secondary to side branch occlusion (diagonal branch). One
transient ischaemic attack. 
Out hospital follow up at 22 months (12-27) no stent thrombosis occured.
One patient died of cranial traumatism; two patients (1%) had restenosis at
the margin of the BVS requiring repeated angioplasty. 
Conclusion at nearly two years follow up, our data confirm the safety of
the device and the low rate of reintervention.
The author hereby declares no conflict of interest
0234
Drug-eluting stents versus bare-metal stent in large coronary arteries
Majed Hassine*, Mehdi Boussada, Mejdi Ben Massoud, Marouen
Mahjoub, Zohra Dridi, Fethi Betbout, Habib Gamra
Hôpital F. Bourguiba, Monastir, Tunisie
*Corresponding author: majed.hassine18@gmail.com (Majed Hassine)
Background Although drug-eluting stents (DES) have been shown to dra-
matically reduce restenosis and improve the rate of event-free survival, the
benefit of DES appears to be limited to restenosis. In this retrospective, single-
center study we aimed to compare the long-term outcomes of DES versus
bare-metal stent (BMS) in large coronary arteries (diameter ≥3.5mm).
Methods A total of 164 consecutive patients (mean age 60 years) required
percutaneous coronary intervention with stents ≥3.5mm in diameter, 84 were
BMS and 80 DES. The primary endpoint was major adverse cardiac events
(MACE) defined as angiographically defined in-stent restenosis (ISR), stent
thrombosis and death from any cause.
Results A mean clinical follow up of 28 months was obtained. The DES
group had higher rates of diabetes (63% vs 37%, p=0.001), previous CAD
(74% vs 25%, p=0.001) and previous PCI (69% vs 31%, p=<0.04). There was
no significant difference between the two groups regarding the rate of hyper-
tension, dyslipidemia, smokers and the mean left ventricular ejection fraction.
There was a higher average stent length in the DES group (18.7 vs 16.3,
p=0.011) as well as a lower average stent diameter (3.54 vs 3.63, p=0.003).
There was a significant difference in MACE between the two groups in favour
of DES (11.3% DES vs 23.8% BMS group, p=0.04) at 28 months. The rate of
in-stent restenosis (ISR) was significantly reduced among patients receiving
DES with ISR rates of 15.8% among patients receiving DES compared to
41.7% among those receiving BMS (p=0.025). There were no significant dif-
ferences in the rate of death or stent thrombosis.
Conclusion In patients requiring stenting of large coronary arteries, there
was reduced MACE in patients treated with DES. This benefit was primarily
driven by decreased in-stent restenosis rate.
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Aims To demonstrate the acute and early outcomes of the Nile PAX dedi-
cated polymer-free paclitaxel-coated stents in the treatment of the coronary
bifurcation lesions. 
Methods and results The Nile PAX device incorporates a cobalt-chromium
alloy with a side aperture in the mid-stent designed to optimize scaffold at the
bifurcation carina and side branch (SB) ostium, while maintaining SB access
during procedure. From January 2012 to December 2014, 36 patients were
included in a retrospective, monocentric study. Lesion criteria were: vessel size
2.5-3.5mm in the parent vessel (PV) and 2.0-3.0mm in the SB, regardless of the
lesion length. Average age was 63,1 years, 22% of patientshad diabetesand 51%
had acute coronary syndrome, while LAD/Dg was involved in 67% of cases.
Percutaneous coronary intervention (PCI) Ad-Hoc was done for 40%of lesions.
SB received additional stent in 8% of procedures and final kissing-balloon infla-
tion was performed in 89% of procedures. There was three non-Q myocardial
infarctions: one during hospitalization, and two up to 6 months.In addition to
these three Major adverse cardiacevents (MACE), two other patients underwent
a target lesion revascularization due to astable angina.
Conclusions Preliminary results of this retro-prospective monocentric
study demonstrated encouraging results with the Nile PAX bifurcation DES in
the treatment of coronary bifurcation lesions, including high device and pro-
cedural success.
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Introduction Instent restenosis (ISR) remains the weak point of coronary
angioplasty despite the advent of drug-eluting stents.The drug eluting balloon
(DEB), which in contact of the artery wall releases an antiproliferative agent,
could be an option to treat ISR or some de novo lesions. 
Methods Between October 2013 and December 2014 in our center, all
patients treated with DEB for RIS or de novo lesions were identified. ISR was
defined as a stenosis of more than 50% or a measuring FFR≤0,8 to a site pre-
viously treated by stent. The lesion was first treated by compliant balloon then
DEB (SeQuent Please® laboratory Braun® B) was inflated for 30 seconds and
then removed. Angiographic control was achieved and, in case of incomplete
result or complication, a stent could be implanted.
Results Among the 48 patients treated with DEB, 23 were for ISR and 25
for de novo lesions. The average age of patients was 75.7 years. 31% of patients
were part of a long-term anticoagulation for atrial fibrillation. The clinical pre-
sentation was mostly a stable angina (62%). In 26% of ISR, there was in DES
restenosis, the average time of ISR was 2 years±3.9. The average diameter of
the DEB used was 2.4mm±0.4 for an average length of 17mm±4.7mm. For five
patients (10%) has a complement of stent implantation (DES in 60% of cases).
The double antiaggregation was continued during 3.8 months. In-hospital, one
death appeared. In the mean follow up of 6.5 months (maximum one year) no
deaths were reported. After revascularization 8% of patients had a clinical
relapse, 12.5% had a positive ischemic test. In 10.4% of cases, a significant rest-
enosis in angioplasty site DEB (TLR) has been highlighted, and requiring a new
revascularization.The average period for TLR was 7.6 months±4.
Conclusion The DEB is a safe option mainly for ISR and for small caliber
arteries, or bifurcation lesions or in the elderly or in long-term anticoagulation.
The clinical course is often satisfactory. 
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Objectives This work reports the concept and the practical feasibility of
Reversed Single String bifurcation stenting technique by demonstrating three
in vitro cases.
